This webinar introduces a novel therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia, producing complete regression in xenograph mouse models (with minimal effects on body weight). In this webinar, you will learn how this novel compound has superior efficacy over several FDA approved cancer cytidine-based therapeutics (e.g., gemcitabine, azacytidine and decitabine) and why this compound shows promise as a potentially superior therapeutic treatment for colon cancer and leukemia. Among some of the superior aspects of this novel compound are its ability to provide complete and durable tumor regression in study animals beyond post-implant day 150 and its evidence of oral activity, which expands options for route of administration beyond the current FDA approved cytidine-based injectable therapeutics.